MeSH term
Frequency | Condition_Probility | Cell Division/drug effects | 2 | 0.0 |
Humans | 168 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 68 | 0.0 |
*Antigens, CD | 3 | 0.0 |
Disease Progression | 3 | 0.0 |
Female | 70 | 0.0 |
Haptoglobins/*genetics | 16 | 40.0 |
Male | 73 | 0.0 |
Models, Biological | 2 | 0.0 |
Phenotype | 31 | 0.0 |
*Polymorphism, Genetic | 26 | 0.0 |
Sex Factors | 4 | 0.0 |
Alleles | 17 | 0.0 |
Blood Group Antigens/*genetics | 12 | 11.0 |
Chi-Square Distribution | 3 | 0.0 |
Cluster Analysis | 3 | 1.0 |
Ethnic Groups/*genetics | 11 | 5.0 |
Gene Frequency | 29 | 0.0 |
Haplotypes | 4 | 0.0 |
Residence Characteristics | 2 | 10.0 |
English Abstract | 37 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Animals | 42 | 0.0 |
Endocytosis | 2 | 0.0 |
Haptoglobins/*metabolism | 7 | 58.0 |
Hemoglobins/*metabolism | 5 | 12.0 |
Macromolecular Substances | 4 | 0.0 |
Models, Molecular | 4 | 0.0 |
Molecular Sequence Data | 10 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Adult | 42 | 0.0 |
Aged | 19 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Biopsy | 2 | 0.0 |
Middle Aged | 34 | 0.0 |
Comparative Study | 25 | 0.0 |
*Genetic Markers | 6 | 1.0 |
*Heterozygote | 3 | 0.0 |
Kinetics | 9 | 0.0 |
Rats | 7 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Mice | 13 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
DNA/metabolism | 3 | 0.0 |
Protein Binding | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 21 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Time Factors | 2 | 0.0 |
Homozygote | 3 | 0.0 |
Antibody Specificity | 3 | 0.0 |
Chronic Disease | 4 | 0.0 |
DNA/genetics | 2 | 0.0 |
*Gene Pool | 2 | 10.0 |
Russia | 6 | 6.0 |
Blood Proteins/*genetics | 18 | 11.0 |
*Genetics, Population | 14 | 3.0 |
India | 3 | 0.0 |
Polymorphism, Genetic/*genetics | 7 | 0.0 |
Linkage (Genetics) | 5 | 0.0 |
Models, Genetic | 3 | 0.0 |
Polymorphism, Genetic | 11 | 0.0 |
*Gene Frequency | 10 | 1.0 |
Multivariate Analysis | 2 | 0.0 |
Variation (Genetics) | 6 | 0.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Acute Disease | 3 | 0.0 |
Child | 12 | 0.0 |
Child, Preschool | 4 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Infant | 2 | 0.0 |
Chromosome Mapping | 8 | 0.0 |
*Phenotype | 3 | 1.0 |
Evaluation Studies | 4 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Drug Interactions | 2 | 0.0 |
Haptoglobins/*pharmacology | 2 | 66.0 |
Japan | 2 | 0.0 |
*Magnetic Resonance Imaging | 2 | 1.0 |
Adolescent | 14 | 0.0 |
Emigration and Immigration | 3 | 6.0 |
Erythrocytes/*enzymology | 7 | 1.0 |
Factor Analysis, Statistical | 3 | 7.0 |
Gene Frequency/*genetics | 4 | 2.0 |
Heterozygote Detection | 2 | 0.0 |
Siberia | 3 | 7.0 |
Blood Proteins/*analysis | 4 | 2.0 |
Prognosis | 3 | 0.0 |
Africa/ethnology | 2 | 4.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Brazil | 2 | 0.0 |
Swine | 2 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Base Sequence | 8 | 0.0 |
Blotting, Western | 2 | 0.0 |
Pedigree | 6 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Amino Acids/*urine | 3 | 27.0 |
Desmosine/*urine | 2 | 66.0 |
Europe/ethnology | 3 | 3.0 |
Haptoglobins/*analysis | 4 | 30.0 |
Isoelectric Focusing | 4 | 0.0 |
Jews/*genetics | 2 | 1.0 |
Genetic Markers/*genetics | 5 | 4.0 |
ABO Blood-Group System/genetics | 5 | 11.0 |
Case-Control Studies | 2 | 0.0 |
Complement 3/genetics | 2 | 5.0 |
Genetic Markers | 15 | 0.0 |
Transferrin/genetics | 4 | 8.0 |
Venezuela | 2 | 6.0 |
Genetic Markers/genetics | 4 | 0.0 |
Heterozygote | 6 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
*Alleles | 2 | 0.0 |
Italy | 4 | 0.0 |
Transferrin/*genetics | 3 | 6.0 |
*Genetic Heterogeneity | 2 | 1.0 |
Phylogeny | 2 | 0.0 |
Spain | 2 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Prevalence | 2 | 0.0 |
Blood Group Antigens/genetics | 8 | 13.0 |
Haptoglobins/genetics | 5 | 10.0 |
Vitamin D-Binding Protein/genetics | 2 | 7.0 |
Oxidation-Reduction | 2 | 0.0 |
Spectrophotometry, Ultraviolet | 3 | 1.0 |
Epitopes/analysis | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Helicobacter pylori/immunology/*isolation & purification | 2 | 50.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Creatinine/urine | 2 | 1.0 |
Pregnancy | 3 | 0.0 |
Reference Values | 3 | 0.0 |
Biological Markers/urine | 2 | 3.0 |
Blood Proteins/genetics | 3 | 5.0 |
Erythrocytes/enzymology | 9 | 2.0 |
Enzymes/*genetics | 2 | 4.0 |
Genetics, Population | 3 | 0.0 |
Liver/metabolism | 4 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Restriction Mapping | 2 | 0.0 |
alpha 1-Antitrypsin/genetics | 2 | 9.0 |
ABO Blood-Group System/*genetics | 2 | 4.0 |
Gene Frequency/genetics | 5 | 1.0 |
Hamsters | 2 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Cattle | 2 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Age Factors | 2 | 0.0 |
*Ethnic Groups | 4 | 3.0 |
Enzymes/genetics | 3 | 9.0 |
Inuits/*genetics | 2 | 15.0 |
Lod Score | 2 | 0.0 |
Cell Line | 5 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Helicobacter Infections/*diagnosis | 2 | 50.0 |
*Helicobacter pylori | 2 | 1.0 |
Recombination, Genetic | 3 | 0.0 |
Horses | 2 | 1.0 |
Amino Acids/analysis | 2 | 0.0 |
Binding Sites | 7 | 0.0 |
Protein Conformation | 4 | 0.0 |
*Linkage (Genetics) | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 7 | 0.0 |
Molecular Weight | 3 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
Rh-Hr Blood-Group System/genetics | 3 | 10.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
DNA Probes | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Genotype | 3 | 0.0 |
USSR | 4 | 22.0 |
Immunoblotting | 2 | 0.0 |
Hemoglobins/metabolism | 4 | 2.0 |
*Blood Stains | 2 | 5.0 |
Blotting, Southern | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Mutation | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Korea | 2 | 0.0 |
Blood Grouping and Crossmatching | 2 | 2.0 |
Chromatography, Affinity | 3 | 0.0 |
Rabbits | 4 | 0.0 |
Enzymes/blood/*genetics | 2 | 33.0 |
*Chromosomes, Human, Pair 16 | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Plasmids | 2 | 0.0 |
*Blood Group Antigens | 2 | 3.0 |
Karyotyping | 3 | 0.0 |
*Genes, Structural | 2 | 0.0 |
Chemistry | 3 | 1.0 |
HLA Antigens/*genetics | 2 | 0.0 |
*Indians, South American | 2 | 8.0 |
Complement 6/*genetics | 2 | 14.0 |
Neuraminidase/pharmacology | 2 | 2.0 |
Acetylation | 3 | 0.0 |
